Events & Press

Santen’s Tampere manufacturing facility to be acquired by NextPharma

25.01.2019

 – Tampere, Finland –

Santen SA and NextPharma today announce

that Santen’s Tampere manufacturing facility and related operations will be acquired by NextPharma, a leading European pharmaceutical Contract Development and Manufacturing Organisation (CDMO). The acquisition is expected to be completed in the summer of 2019. The companies are entering into a strategic partnership that will see NextPharma take over production of Santen products in the Tampere facility.

 

NextPharma will be taking over the site fully staffed, with 181 employees involved in manufacturing and its support functions, including quality control, quality assurance, IT and administration, transferring to NextPharma. A large number of Santen employees in Finland not necessarily linked to Manufacturing or its functions, such as Sales and Marketing, R&D, Regulatory, Quality Assurance, Pharmacovigilance, Human Resources, IT and Administration will not be affected by the  acquisition and those roles will continue being part of Santen.

 

“Since 1997, Santen has benefited tremendously from the expertise and commitment of our colleagues here in Tampere which has contributed so significantly to the growth of the Santen business in the region. We are pleased that through the acquisition of the site by NextPharma, we both increase the flexibility and efficiency for Santen’s supply chain and at the same time generate an exciting future for our people by becoming the centre of excellence for ophthalmology and blow fill seal technology (BFS) within the NextPharma manufacturing network. Santen’s goal of securing sustainable growth as a specialised pharmaceutical company with a global presence is now one step closer,” commented Katri Outinen, Managing Director, Santen Oy.

 

Peter Burema, CEO of NextPharma, welcomed the strategic partnership: “This is an important moment for NextPharma as a leading European Contract and Development Manufacturing Organisation. Through this acquisition, Tampere will add ophthalmology manufacturing and sterile blow fill seal (BFS) technology and will provide an excellent extension to our six other manufacturing sites in Europe, each of them with their own specific technologies and/or therapeutic classes of medicine. The extensive experience that the Santen team will bring is key to the continuity of production of the highest quality products, and we are eager to welcome them to the NextPharma family.”

 

 

- ENDS -

 

For more information contact:

Katri Outinen, Managing Director, Santen Oy, +358 40 533 8152, katri.outinen@santen.com

Peter Burema, Chief Executive Officer, NextPharma, +44 1483 479 120, peter.burema@nextpharma.com or Alan Dodsworth, Chief M&A Officer, NextPharma, +44 1483 479 120, alan.dodsworth@nextpharma.com

 

Notes to editors

About Santen

As a specialised company dedicated to the ophthalmic field, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products and devices. Santen has long been the market leader in Japan for prescription ophthalmic pharmaceuticals and is now a leader in the sector in the EMEA (Europe, Middle East and Africa) region. With scientific knowledge and organisational capabilities nurtured over nearly 130 years, Santen products and services now reach over 60 countries, contributing to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen websites www.santen.com (global) and www.santen.eu (EMEA).

About NextPharma

NextPharma is a leading European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with a current footprint spanning five sites in Germany and one in France. NextPharma supplies products globally, with five of its six sites FDA-approved. With expertise in solids, semi solids and non-sterile liquids, the company provides services from pharmaceutical development, clinical supplies, scale-up and process validation through to commercial manufacturing for a large range of dosage forms including tablets, capsules, granules, powders, pellets, gels, creams, sprays and syrups. Additionally, it provides a wide range of packaging solutions including blisters, bottles, sachets, stick packs and tubes. NextPharma’s expertise and centres of excellence enable it to provide a unique service offering in certain very specific specialised areas such as hormonal solids and semi-solids, cephalosporins, penicillins, narcotics, modified release products, as well as paediatric medicinal products. For more information, please visit www.nextpharma.com.

Bitte hier für die deutsche Version klicken.